Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Our pipeline is based on our platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway.
Evidence suggests that potent and selective inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of functioning synapses associated with cognitive and functional decline in complement-mediated neurodegeneration. Our product candidates are designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Oct 04, 2021 |Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer
Sep 23, 2021 |Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
Sep 20, 2021 |Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event